Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-8gtf8 Total loading time: 0 Render date: 2025-02-23T13:08:19.421Z Has data issue: false hasContentIssue false

Rotigotine

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Rotigotine ((–)-(S)-5,6,7,8-tetrahydro-6-{propyl[2-(2-thienyl)ethyl]amino}-1-naphthol or (6S)-6-(propyl[2-(-thienyl)ethyl]amino)-5,6,7,8-tetrahydro-1-naphthalenol) is a white to off-white crystalline powder, lipophilic and poorly water-soluble at neutral pH, whereas solubility increases at more acidic pH. It has a molecular weight of 315.5 and an empirical formula of C19H25NOS.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 424 - 436
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Lau, YH, Leta, V, Rukavina, K, Parry, M, Natividad, JA, Metta, V, Chung-Faye, G, CHaudhuri, KR. Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease. J Neural Transm (Vienna) 2022; 129(7): 889–894.CrossRefGoogle ScholarPubMed
Raeder, V, Boura, I, Leta, V, Jenner, P, Reichmann, H, Trenkwalder, C, Klingelhoefer, L, Chaudhuri, KR. Rotigotine transdermal patch for motor and non-motor Parkinson’s disease: a review of 12 years’ clinical experience. CNS Drugs 2021; 35(2): 215–231.CrossRefGoogle ScholarPubMed
Ray Chaudhuri, K, Martinez-Martin, P, Antonini, A, Brown, RG, Friedman, JH, Onofrj, M, Surmann, E, Ghys, L, Trenkwalder, C. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013; 19(7): 660–665.CrossRefGoogle ScholarPubMed
Rosa-Grilo, M, Qamar, MA, Taddei, RN, Pagonabarraga, J, Kulisevsky, J, Sauerbier, A, Chaudhuri, KR. Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now? NPJ Parkinsons Dis 2017; 3: 28.CrossRefGoogle ScholarPubMed
Todorova, A, Martinez-Martin, P, Martin, A, Rizos, A, Reddy, P, Chaudhuri, KR. Daytime apomorphine infusion combined with transdermal Rotigotine patch therapy is tolerated at 2 years: a 24-h treatment option in Parkinson’s disease. Basal Ganglia 2013; 3(2): 127–130.CrossRefGoogle Scholar
Trenkwalder, C, Kies, B, Rudzinska, M, Fine, J, Nikl, J, Honczarenko, K, Dioszeghy, P, Hill, D, Anderson, T, Myllyla, V, Kassubek, J, Stieger, M, Zucconi, M, Tolosa, E, Poewe, W, Surmann, E, Whitesides, J, Boroojerdi, B, Chaudhuri, KR; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26(1): 90–99.CrossRefGoogle ScholarPubMed

References

AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 31 May 2022 via www.medicinescomplete.com.Google Scholar
Chung, SJ, Kim, JM, Kim, JW, Jeon, BS, Singh, P, Thierfelder, S, Ikeda, J, Bauer, L; Asia Pacific Rotigotine Switching Study Group. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson’s disease: an open-label study. Expert Opin Pharmacother 2015; 16(7): 961–970.CrossRefGoogle ScholarPubMed
Elmer, LW, Surmann, E, Boroojerdi, B, Jankovic, J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012; 18(5):488–493.CrossRefGoogle ScholarPubMed
Hattori, N, Mochizuki, H, Hasegawa, K, Nomoto, M, Uchida, E, Terahara, T, Okawa, K, Fukuta, HR. Ropinirole patch versus placebo, ropinirole extended-release tablet in advanced Parkinson’s disease. Mov Disord 2020; 35(9): 1565–1573.CrossRefGoogle ScholarPubMed
Ibrahim, H, Woodward, Z, Pooley, J, Richfield, EW. Rotigotine patch prescription in inpatients with Parkinson’s disease: evaluating prescription accuracy, delirium and end-of-life use. Age Ageing 2021; 50(4): 1397–1401.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 31 May 2022 via www.medicinescomplete.com.Google Scholar
Koschel, J, Chaudhuri, KR, Tönges, L, Thiel, M, Raeder, V, Jott, WH. Implications of dopaminergic medication withdrawal in Parkinson’s disease. J Neural Transm (Vienna) 2022; 129(9): 1169–1178.CrossRefGoogle ScholarPubMed
Latt, MD, Lewis, S, Zekry, O, Fung, VSC. Factors to consider in the selection of dopamine agonists for older persons with Parkinson’s disease. Drugs Aging 2019; 36(3): 189–202.CrossRefGoogle ScholarPubMed
LeWitt, PA, Boroojerdi, B, Surmann, E, Poewe, W; SP716 Study Group; SP715 Study Group. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm (Vienna) 2013; 120(7): 1069–1081.CrossRefGoogle Scholar
Pierantozzi, M, Placidi, F, Liguori, C, Albanese, M, Imbriani, P, Marciani, MG, Mercuri, NB, Stanzione, P, Stefani, A. Rotigotine may improve sleep architecture in Parkinson’s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med 2016; 21: 140–144.CrossRefGoogle ScholarPubMed
Rotigotine. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 31 May 2022 via www.medicinescomplete.com.Google Scholar
Summary of product characteristics – Neupro 4 mg/24 h transdermal patch. UCB Pharma Limited. Electronic Medicines Compendium: Neupro 4 mg/24 h transdermal patch – summary of product characteristics (SmPC) – (emc). Accessed on 31 May 2022 via www.medicines.org.uk.Google Scholar
Taguchi, S, Koide, H, Oiwa, H, Hayashi, M, Ogawa, K, Ito, C, Nakashima, K, Yuasa, T, Yasumoto, A, Ando, H, Fujikake, A, Fukuoka, T, Tokui, K, Izuma, M, Tsunoda, Y, Kawagashira, Y, Okada, Y, Niwa, JI, Doyu, M. Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease. PLoS One 2021; 16(7): e0255274.CrossRefGoogle ScholarPubMed
Trenkwalder, C., Kies, B, Dioszeghy, P, Hill, D, Surmann, E, Boroojerdi, B, Whitesides, J, Chaudhuri, KR. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia 2012; 2(2): 79–85CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Rotigotine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.044
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Rotigotine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.044
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Rotigotine
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.044
Available formats
×